• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不列颠哥伦比亚省华裔居民慢性淋巴细胞白血病低发病率的保持情况:1983年至2008年的26年调查

Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008.

作者信息

Mak Vivien, Ip Dennis, Mang Oscar, Dalal Chinmay, Huang Steven, Gerrie Alina, Gillan Tanya, Ramadan Khaled M, Toze Cynthia, Au Wing-Yan

机构信息

Department of Medicine and Geriatrics, Princess Margaret Hospital , Hong Kong.

出版信息

Leuk Lymphoma. 2014 Apr;55(4):824-7. doi: 10.3109/10428194.2013.827785. Epub 2013 Sep 12.

DOI:10.3109/10428194.2013.827785
PMID:23909397
Abstract

The incidence of chronic lymphocytic leukemia (CLL) in the Asian population is up to 10 times lower than that in Caucasians. Studies on CLL in Asian residents in North America may help to determine the relative genetic and environmental causes of such a difference. Computerized records of CLL incidence from the combined British Columbia (BC) databases (n = 2736) and the Hong Kong Cancer Registry (HKCR, n = 572) were traced. Ethnic Chinese cases of CLL in BC were identified (n = 35). The world age standardized rates (WASRs) of CLL (per 100 000) were calculated in BC (1.71), HK (0.28) and BC Chinese (0.4), respectively. Using standard incidence ratios (SIRs), the observed BC Chinese case number was comparable to the figure projected from HK rates (SIR 1.3, p = 0.1) but significantly lower than the figure following BC rates (SIR 0.22, p < 0.0001). The difference was maintained over both genders, in all age groups and through the years. Our data over three decades suggest that genetic factors outplay environmental factors to give lower CLL rates in Chinese.

摘要

亚洲人群中慢性淋巴细胞白血病(CLL)的发病率比白种人低达10倍。对北美亚裔居民的CLL研究可能有助于确定造成这种差异的相对遗传和环境因素。追溯了来自不列颠哥伦比亚省(BC)综合数据库(n = 2736)和香港癌症登记处(HKCR,n = 572)的CLL发病率计算机记录。确定了BC省的华裔CLL病例(n = 35)。分别计算了BC省(1.71)、香港(0.28)和BC省华裔(0.4)的CLL世界年龄标准化发病率(每10万人)。使用标准化发病率(SIR),观察到的BC省华裔病例数与根据香港发病率预测的数字相当(SIR 1.3,p = 0.1),但显著低于按照BC省发病率预测的数字(SIR 0.22,p < 0.0001)。这种差异在所有性别、所有年龄组以及多年来都持续存在。我们三十年的数据表明,遗传因素比环境因素对中国人较低的CLL发病率影响更大。

相似文献

1
Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008.不列颠哥伦比亚省华裔居民慢性淋巴细胞白血病低发病率的保持情况:1983年至2008年的26年调查
Leuk Lymphoma. 2014 Apr;55(4):824-7. doi: 10.3109/10428194.2013.827785. Epub 2013 Sep 12.
2
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey.移居到不列颠哥伦比亚省的中国人中,浆细胞肿瘤的发病率较低:一项长达 30 年的调查结果。
Leuk Lymphoma. 2011 Dec;52(12):2316-20. doi: 10.3109/10428194.2011.601475. Epub 2011 Aug 18.
3
Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey.不列颠哥伦比亚省华裔移民中的霍奇金淋巴瘤:一项为期25年的调查。
Ann Oncol. 2004 Apr;15(4):626-30. doi: 10.1093/annonc/mdh132.
4
Genetic susceptibility for chronic lymphocytic leukemia among Chinese in Hong Kong.香港华人慢性淋巴细胞白血病的遗传易感性。
Eur J Haematol. 2010 Dec;85(6):492-5. doi: 10.1111/j.1600-0609.2010.01518.x.
5
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data.1953 - 2012年挪威慢性淋巴细胞白血病发病率和生存率的全国趋势:基于人群数据的系统分析
Cancer Med. 2016 Dec;5(12):3588-3595. doi: 10.1002/cam4.849. Epub 2016 Nov 4.
6
Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia.不列颠哥伦比亚省华裔移民中非霍奇金淋巴瘤的发病率及谱系
Br J Haematol. 2005 Mar;128(6):792-6. doi: 10.1111/j.1365-2141.2005.05387.x.
7
Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.美国和英国慢性白血病患者的生存率:年龄相关差异及21世纪初的变化
Eur J Haematol. 2015 Jun;94(6):540-5. doi: 10.1111/ejh.12468. Epub 2015 Feb 4.
8
Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization.加拿大不列颠哥伦比亚省接受细胞遗传学检测的慢性淋巴细胞白血病患者遗传图谱的人群特征分析:省级实验室标准化的作用
Cancer Genet. 2014 Jul-Aug;207(7-8):316-25. doi: 10.1016/j.cancergen.2014.08.006. Epub 2014 Aug 29.
9
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.慢性淋巴细胞白血病长期存活者群体中其他癌症的发病率及预后影响
Ann Oncol. 2016 Jun;27(6):1100-1106. doi: 10.1093/annonc/mdw072. Epub 2016 Feb 23.
10
Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.加拿大不列颠哥伦比亚省基于人群的病例系列分析:接受同种异体造血干细胞移植的 HLA-B27 阳性慢性淋巴细胞白血病患者结局更差吗?
Leuk Res. 2019 Sep;84:106193. doi: 10.1016/j.leukres.2019.106193. Epub 2019 Jul 15.

引用本文的文献

1
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.中国和美国慢性淋巴细胞白血病患者特征、治疗及生存结局的比较分析。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf181.
2
A 47-Year-old Asian female with tracheobronchial space-occupying lesions caused by chronic lymphocytic leukemia.一位 47 岁的亚裔女性,患有慢性淋巴细胞白血病导致的气管支气管腔占位性病变。
BMC Pulm Med. 2024 Oct 14;24(1):514. doi: 10.1186/s12890-024-03330-0.
3
Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.
全球 miRNA 谱分析揭示了导致亚洲和西方人群慢性淋巴细胞白血病发病率不同的关键分子。
Haematologica. 2024 Feb 1;109(2):479-492. doi: 10.3324/haematol.2023.283181.
4
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea.韩国慢性淋巴细胞白血病患者的多中心回顾性分析。
Blood Res. 2021 Dec 31;56(4):243-251. doi: 10.5045/br.2021.2021102.
5
Ethnic and geographic diversity of chronic lymphocytic leukaemia.慢性淋巴细胞白血病的种族和地域多样性。
Leukemia. 2021 Feb;35(2):433-439. doi: 10.1038/s41375-020-01057-5. Epub 2020 Oct 19.
6
Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.奥滨尤妥珠单抗在中国 B 细胞淋巴瘤患者中的安全性和有效性:GERSHWIN 试验的二次分析。
Cancer Commun (Lond). 2018 May 30;38(1):31. doi: 10.1186/s40880-018-0300-5.
7
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.伊布替尼与利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤:一项随机、开放标签的 3 期研究。
Cancer Med. 2018 Apr;7(4):1043-1055. doi: 10.1002/cam4.1337. Epub 2018 Mar 13.
8
Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.中国慢性淋巴细胞白血病患者的临床病理特征及预后
Oncotarget. 2017 Apr 11;8(15):25455-25468. doi: 10.18632/oncotarget.16037.
9
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病预后指数:一种预测中国慢性淋巴细胞白血病患者首次治疗时间的新型综合评分系统。
Chin Med J (Engl). 2017 Jan 20;130(2):135-142. doi: 10.4103/0366-6999.197978.
10
Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.奥妥珠单抗在中国B细胞淋巴瘤患者中的药代动力学
Br J Clin Pharmacol. 2017 Jul;83(7):1446-1456. doi: 10.1111/bcp.13232. Epub 2017 Feb 14.